These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32497363)

  • 21. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.
    Pires S; Sevivas T; Loureiro CC; Bartholomé B
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real-life experience.
    Drillaud N; Babuty A; Rugeri L; Fouassier M; Lienhart A; Béné MC; Lefranc C; Ternisien C; Chamouard V; Sigaud M; Pennetier M; Trossaërt M; Meunier S
    Haemophilia; 2020 Nov; 26(6):e349-e352. PubMed ID: 32815608
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
    Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
    Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials of the recombinant factor VIII product, Kogenate.
    Inwood M; Lusher J
    Transfus Med Rev; 1992 Oct; 6(4):261-2. PubMed ID: 1421826
    [No Abstract]   [Full Text] [Related]  

  • 29. Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
    Motwani J; Guillet B; Blatny J; Schilling FH; Wibaut B; Goldstine J; Nagy A; Doralt J; Engl W; Tangada S; Spotts G
    Haemophilia; 2020 May; 26(3):478-486. PubMed ID: 32338433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.
    Nijdam A; Kurnik K; Liesner R; Ljung R; Nolan B; Petrini P; Fischer K;
    Haemophilia; 2015 Jul; 21(4):444-50. PubMed ID: 25582494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihaemophilic cryoprecipitate from fresh plasma and its use in haemophilia.
    Brüster H; Glassner K; Riech PC
    Ger Med Mon; 1968 Mar; 13(3):129-33. PubMed ID: 5656869
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspects of the management of hemophilia in childhood. Availability of newer concentrates of antihemophilic factor failitates management.
    Strauss HS
    R I Med J; 1966 Aug; 49(8):466-8. PubMed ID: 5222119
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
    Shafer F; Charnigo RJ; Plotka A; Baumann J; Liang Y; Korth-Bradley J
    Clin Pharmacol Drug Dev; 2015; 4(3):237-41. PubMed ID: 27140804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of various factor VIII concentrates used in treatment of haemophilia A.
    Nilsson IM; Hedner U
    Br J Haematol; 1977 Dec; 37(4):543-57. PubMed ID: 304740
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryoprecipitate in the management of haemophilia in Kenya.
    Taylor JR; Ahluwalia NS; Morrison CJ; Kaviti JN; Cardwell CL
    East Afr Med J; 1969 Feb; 46(2):121-8. PubMed ID: 5798053
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibitor development, safety, and efficacy of Advate
    Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
    Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
    Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hemophilia and related diseases, with special reference to therapeutic policy].
    Nagao T
    Nihon Rinsho; 1974 May; 32(5):993-9. PubMed ID: 4603576
    [No Abstract]   [Full Text] [Related]  

  • 40. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027.
    Reding MT; Pabinger I; Lalezari S; Santagostino E; Mancuso ME
    Haemophilia; 2020 Jul; 26(4):e201-e204. PubMed ID: 32578323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.